- Home
- HSDT vs RPID Comparison
HSDT vs RPID Comparison
Compare HSDT & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSDT | RPID |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 84.8M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HSDT | RPID |
|---|---|---|
| Price | $2.42 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $8.00 |
| AVG Volume (30 Days) | 224.5K | ★ 227.1K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.27 | 2.78 |
| EPS | N/A | ★ N/A |
| Revenue | $6,017,000.00 | ★ $33,587,000.00 |
| Revenue This Year | $91.56 | $19.12 |
| Revenue Next Year | N/A | $18.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1057.12 | 19.74 |
| 52 Week Low | $1.19 | $1.52 |
| 52 Week High | $25.50 | $4.94 |
Technical Indicators
Market Signals| Indicator | HSDT | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 74.56 | 36.60 |
| Support Level | $1.90 | $1.52 |
| Resistance Level | $3.68 | $2.18 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 96.51 | 37.04 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.